OLMA Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Olema Pharmaceuticals's net margin of -49.65%. Olema Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Olema Pharmaceuticals has a consensus price target of $28.00, signalling upside risk potential of 386.96%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 483.4%. Given that NovaBay Pharmaceuticals has higher upside potential than Olema Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Olema Pharmaceuticals.

Olema Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Olema Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Olema Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Olema Pharmaceuticals's net income of -$34.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Olema Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to Olema Pharmaceuticals's net margin of 25.23%. Olema Pharmaceuticals's return on equity of -- beat Pfizer's return on equity of 4.63%.

Olema Pharmaceuticals has a consensus price target of $28.00, signalling upside risk potential of 386.96%. On the other hand Pfizer has an analysts' consensus of $31.78 which suggests that it could grow by 18.3%. Given that Olema Pharmaceuticals has higher upside potential than Pfizer, analysts believe Olema Pharmaceuticals is more attractive than Pfizer.

Olema Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.588%.

Olema Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.26% to investors and pays a quarterly dividend of $0.42 per share. Olema Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Olema Pharmaceuticals quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.7B. Olema Pharmaceuticals's net income of -$34.6M is lower than Pfizer's net income of $4.5B. Notably, Olema Pharmaceuticals's price-to-earnings ratio is -- while Pfizer's PE ratio is 36.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals is -- versus 2.57x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics has a net margin of -- compared to Olema Pharmaceuticals's net margin of -54.2%. Olema Pharmaceuticals's return on equity of -- beat PTC Therapeutics's return on equity of --.

Olema Pharmaceuticals has a consensus price target of $28.00, signalling upside risk potential of 386.96%. On the other hand PTC Therapeutics has an analysts' consensus of $58.36 which suggests that it could grow by 29.57%. Given that Olema Pharmaceuticals has higher upside potential than PTC Therapeutics, analysts believe Olema Pharmaceuticals is more attractive than PTC Therapeutics.

Olema Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.619, suggesting its less volatile than the S&P 500 by 38.129%.

Olema Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

Olema Pharmaceuticals quarterly revenues are --, which are smaller than PTC Therapeutics quarterly revenues of $196.8M. Olema Pharmaceuticals's net income of -$34.6M is higher than PTC Therapeutics's net income of -$106.7M. Notably, Olema Pharmaceuticals's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals is -- versus 3.82x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Olema Pharmaceuticals's net margin of -2357.27%. Olema Pharmaceuticals's return on equity of -- beat Palatin Technologies's return on equity of --.

Olema Pharmaceuticals has a consensus price target of $28.00, signalling upside risk potential of 386.96%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1316.67%. Given that Palatin Technologies has higher upside potential than Olema Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Olema Pharmaceuticals.

Olema Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

Olema Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Olema Pharmaceuticals quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Olema Pharmaceuticals's net income of -$34.6M is lower than Palatin Technologies's net income of -$7.8M. Notably, Olema Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.